Hoy J - Search Results

1

Recommendations for evaluation and management of bone disease in HIV.

Brown TT, Hoy J, Borderi M, Guaraldi G, Renjifo B, Vescini F, Yin MT, Powderly WG. Brown TT, et al. Among authors: hoy j. Clin Infect Dis. 2015 Apr 15;60(8):1242-51. doi: 10.1093/cid/civ010. Epub 2015 Jan 21. Clin Infect Dis. 2015. PMID: 25609682 Free PMC article.

2

Ten years of highly active antiretroviral therapy for HIV infection.

Chen LF, Hoy J, Lewin SR. Chen LF, et al. Among authors: hoy j. Med J Aust. 2007 Feb 5;186(3):146-51. doi: 10.5694/j.1326-5377.2007.tb00839.x. Med J Aust. 2007. PMID: 17309405 Review.

3

Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.

Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Belloso WH, Molina JM, Li L, Avihingsanon A, Gazzard B, Cooper DA, Emery S; Altair Study Group. Puls RL, et al. Clin Infect Dis. 2010 Oct 1;51(7):855-64. doi: 10.1086/656363. Clin Infect Dis. 2010. PMID: 20735258 Clinical Trial.

4

Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.

Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, Gouillou M, Schlub TE, Davenport M, Crowe S, Elliott J, Hoy J, Fairley C, Stewart G, Cameron P, Lewin SR. Rajasuriar R, et al. Among authors: hoy j. J Infect Dis. 2010 Oct 15;202(8):1254-64. doi: 10.1086/656369. J Infect Dis. 2010. PMID: 20812848

5

Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy.

Wightman F, Solomon A, Khoury G, Green JA, Gray L, Gorry PR, Ho YS, Saksena NK, Hoy J, Crowe SM, Cameron PU, Lewin SR. Wightman F, et al. Among authors: hoy j. J Infect Dis. 2010 Dec 1;202(11):1738-48. doi: 10.1086/656721. Epub 2010 Oct 27. J Infect Dis. 2010. PMID: 20979453

6

Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection.

Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. Lichtfuss GF, et al. Among authors: hoy j. Biomark Med. 2011 Apr;5(2):171-86. doi: 10.2217/bmm.11.15. Biomark Med. 2011. PMID: 21473720 Review.

7

Bone, fracture and frailty.

Hoy J. Hoy J. Curr Opin HIV AIDS. 2011 Jul;6(4):309-14. doi: 10.1097/COH.0b013e3283478741. Curr Opin HIV AIDS. 2011. PMID: 21537171 Review.

8

Abacavir exposure and cardiovascular risk factors in HIV-positive patients with coronary heart disease: a retrospective case-control study.

Trevillyan JM, Cheng AC, Hoy J. Trevillyan JM, et al. Among authors: hoy j. Sex Health. 2013 May;10(2):97-101. doi: 10.1071/SH12081. Sex Health. 2013. PMID: 23256968

9

Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy.

Hoy J, Grund B, Roediger M, Ensrud KE, Brar I, Colebunders R, Castro ND, Johnson M, Sharma A, Carr A; INSIGHT SMART Body Composition Substudy Group. Hoy J, et al. J Bone Miner Res. 2013 Jun;28(6):1264-74. doi: 10.1002/jbmr.1861. J Bone Miner Res. 2013. PMID: 23299909 Free PMC article. Clinical Trial.

10

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.

INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

468 results

Search Page